Navigation Links
Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
Date:3/13/2008

ment for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the ability of Boston Scientific Corporation to successfully manufacture, market and sell their paclitaxel-eluting coronary stent products; the continued availability of capital to finance our activities; our ability to achieve the financial benefits expected as a result of the acquisition of American Medical Instruments Holdings, Inc. ("AMI"); a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Pfenex Inc. (NYSE MKT: PFNX), ... high-value and difficult to manufacture proteins including biosimilar therapeutics, ... 21 st Annual NewsMakers in the Biotech Industry ... Bertrand Liang , chief executive officer of Pfenex, will ... business strategy on Friday, September 26, 2014 at 10:00 ...
(Date:9/19/2014)... Charlotte, NC (PRWEB) September 19, 2014 ... Certified Biobased Product Label for its Organic Cotton ... the product’s amount of renewable biobased ingredients meets or ... or intermediate materials composed in whole or in significant ... “This logo/label will allow our Organic cotton to be ...
(Date:9/19/2014)... September 19, 2014 ... http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of the  ...  report to their offering.       (Logo: ... one of the fastest-growing segments in the chromatography ... in 2013, and expected to reach $2.0 billion ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... Spain , available today on PharmaBoardroom.com ... of the Eurozone crisis that rocked the Spanish economy in ... the Spanish pharma community has remained pragmatic in times of ... is still the fifth biggest European market, and the ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... 10, 2009, NeoStem, Inc. (NYSE Alternext US: NBS) (the ... "Alternext") indicating that the Company is not in compliance ... "Guide"), which requires a listed company to hold meetings ... Company had announced that it planned to hold a ...
... ITMN ) today announced the pricing of an underwritten ... The last reported sale price of InterMune,s common stock on ... $17.96. The offering is expected to close on or ... All of the shares are being sold by the company.UBS ...
... Pharmacyclics, Inc.,(Nasdaq: PCYC ) today reported financial ... net loss for the second quarter of fiscal 2009,was $4.8 ... of $5.9 million,or $0.23 per share, in the second quarter ... expenses were $4.9 million in the second quarter of fiscal,2009, ...
Cached Biology Technology:NeoStem Receives Notice of Noncompliance from NYSE Alternext US 2InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 2Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 3Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 4Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 5Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 6Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results 7
(Date:9/21/2014)... warming, are set to rise again in 2014 - reaching ... per cent projected rise in burning fossil fuels is revealed ... UK by researchers at the Tyndall Centre for Climate Change ... of Engineering, Mathematics and Physical Sciences at the University of ... Summit, where world leaders will seek to catalyse action on ...
(Date:9/21/2014)... California, San Diego, have developed a program that predicts ... of genes based on sequences of DNA. They describe ... human embryonic cells in a paper published in ... our cells have the same blueprint, the same DNA, ... author of the report. "Skin cells protect, nerve cells ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Program predicts placement of chemical tags that control gene activity 2Battling superbugs 2Battling superbugs 3Battling superbugs 4
... from ESA,s Envisat satellite radar are being used to ... Globe solo round-the-world yacht race. CLS, a subsidiary ... new radar applications division (formerly the BOOST Technologies Company), ... Envisat radar imagery to operationally observe oceans at high ...
... seascape that cleaves earlier each springthey may find relief in ... changes in the timing of sea-ice breakup and of snow ... least some polar bears with an alternative source of food. ... "Over 40 years, six subadult male bears were seen among ...
... battle against invading bacteria reaches its peak activity at ... Experiments with the laboratory model organism, Drosophila melanogaster, reveal ... with the body,s circadian rhythm, according to Stanford researchers ... Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 ...
Cached Biology News:Vendee Globe route seen from above 2Goose eggs may help polar bears weather climate change 2Immunity stronger at night than during day 2
...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Agarose-LE, 250 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Biology Products: